NCT05554328: Testing the Use of the Combination of Selumetinib and Olaparib or Selumetinib Alone Targeted Treatment for RAS Pathway Mutant Recurrent or Persistent Ovarian and Endometrial Cancers, A ComboMATCH Treatment Trial
- State
- Under way
- Phase
- Phase 2
- People
- 165 taking part
- Started
- 25 Apr 2023
- Primary completion
- 23 Sep 2026
- Arms
- Arm I (selumetinib, olaparib)
- Results
- None posted
- 26 Sep 2022: Trial registered
- 25 Apr 2023: Trial started